Search hospitals > Indiana > Michigan City

Woodland Cancer Care Center

Claim this profile
Michigan City, Indiana 46360
Global Leader in Parotid Gland Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Relapse
Conducts research for Breast cancer
94 reported clinical trials
9 medical researchers
Photo of Woodland Cancer Care Center in Michigan CityPhoto of Woodland Cancer Care Center in Michigan CityPhoto of Woodland Cancer Care Center in Michigan City

Summary

Woodland Cancer Care Center is a medical facility located in Michigan City, Indiana. This center is recognized for care of Parotid Gland Cancer, Lung Cancer, Breast Cancer, Relapse, Breast cancer and other specialties. Woodland Cancer Care Center is involved with conducting 94 clinical trials across 201 conditions. There are 9 research doctors associated with this hospital, such as Nibal Saad, Meghana Raghavendra, Taylor M. Ortiz, and Michael Eaton, MD.

Area of expertise

1Parotid Gland Cancer
Global Leader
Woodland Cancer Care Center has run 44 trials for Parotid Gland Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Lung Cancer
Global Leader
Woodland Cancer Care Center has run 20 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage II
Stage I

Top PIs

Clinical Trials running at Woodland Cancer Care Center

Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Ovarian Cancer
Breast cancer
Parotid Gland Cancer
Solid Tumors
ALK Gene Rearrangement
Squamous Cell Carcinoma
Image of trial facility.

T-DM1 + Tucatinib

for Breast Cancer

This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Image of trial facility.

Targeted Therapy

for Solid Tumors

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with some genetic changes or abnormalities (mutations) may benefit from treatment that targets that particular genetic mutation. ComboMATCH is designed to match patients to a treatment that may work to control their tumor and may help doctors plan better treatment for patients with locally advanced or advanced solid tumors.
Recruiting1 award Phase 217 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Woodland Cancer Care Center?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security